Neoadjuvant hormonal therapy prior to radical prostatectomy

F. Civantos, S. Sadek, C. Obek, S. Lai, M. Soloway, S. Howell, M. Gleave, F. Labrie, W. Fair, A. D'Amico, N. Stone, David Grignon

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The US T(2b) study of 3 months of neoadjuvant hormonal therapy (NHT) showed a reduction in the likelihood of positive margins from 48% (control group) to 18% in the treated patients. Follow-up at 42 months shows that the cumulative relapse rate (prostate specific antigen) for 129 patients having NHT was not statistically different from that of the 126 control patients. Because the T(2b) study has been criticized for lacking central pathology review, we present a review of a series involving only one surgeon (MS) and one pathologist (FC) of NHT plus prostatectomy (109 patients) v prostatectomy alone (145 patients) with 24 months' follow-up. Positive margins were decreased from 38% in the untreated to 28% in the treated group, the only statistically significant difference in the results. Biochemical recurrence (PSA >0.2 ng/mL) was higher in the treated group, reflecting selection of more aggressive tumors for NHT, but the difference was not statistically significantly. The incidence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis was similar in the two groups. The largest nonrandomized experience with NHT shows a decrease in the incidence of positive surgical margins when used in high-risk patients with clinically localized carcinoma of the prostate. However, it does not have an impact on disease-free survival at a mean 24-month follow-up.

Original languageEnglish (US)
Pages (from-to)201-206
Number of pages6
JournalMolecular Urology
Volume3
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Prostatectomy
Recurrence
Seminal Vesicles
Incidence
Prostate-Specific Antigen
Disease-Free Survival
Prostate
Lymph Nodes
Pathology
Neoplasm Metastasis
Carcinoma
Control Groups
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Civantos, F., Sadek, S., Obek, C., Lai, S., Soloway, M., Howell, S., ... Grignon, D. (1999). Neoadjuvant hormonal therapy prior to radical prostatectomy. Molecular Urology, 3(3), 201-206.

Neoadjuvant hormonal therapy prior to radical prostatectomy. / Civantos, F.; Sadek, S.; Obek, C.; Lai, S.; Soloway, M.; Howell, S.; Gleave, M.; Labrie, F.; Fair, W.; D'Amico, A.; Stone, N.; Grignon, David.

In: Molecular Urology, Vol. 3, No. 3, 1999, p. 201-206.

Research output: Contribution to journalArticle

Civantos, F, Sadek, S, Obek, C, Lai, S, Soloway, M, Howell, S, Gleave, M, Labrie, F, Fair, W, D'Amico, A, Stone, N & Grignon, D 1999, 'Neoadjuvant hormonal therapy prior to radical prostatectomy', Molecular Urology, vol. 3, no. 3, pp. 201-206.
Civantos F, Sadek S, Obek C, Lai S, Soloway M, Howell S et al. Neoadjuvant hormonal therapy prior to radical prostatectomy. Molecular Urology. 1999;3(3):201-206.
Civantos, F. ; Sadek, S. ; Obek, C. ; Lai, S. ; Soloway, M. ; Howell, S. ; Gleave, M. ; Labrie, F. ; Fair, W. ; D'Amico, A. ; Stone, N. ; Grignon, David. / Neoadjuvant hormonal therapy prior to radical prostatectomy. In: Molecular Urology. 1999 ; Vol. 3, No. 3. pp. 201-206.
@article{6bbbbb451a104fe089877fe28ef15e0d,
title = "Neoadjuvant hormonal therapy prior to radical prostatectomy",
abstract = "The US T(2b) study of 3 months of neoadjuvant hormonal therapy (NHT) showed a reduction in the likelihood of positive margins from 48{\%} (control group) to 18{\%} in the treated patients. Follow-up at 42 months shows that the cumulative relapse rate (prostate specific antigen) for 129 patients having NHT was not statistically different from that of the 126 control patients. Because the T(2b) study has been criticized for lacking central pathology review, we present a review of a series involving only one surgeon (MS) and one pathologist (FC) of NHT plus prostatectomy (109 patients) v prostatectomy alone (145 patients) with 24 months' follow-up. Positive margins were decreased from 38{\%} in the untreated to 28{\%} in the treated group, the only statistically significant difference in the results. Biochemical recurrence (PSA >0.2 ng/mL) was higher in the treated group, reflecting selection of more aggressive tumors for NHT, but the difference was not statistically significantly. The incidence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis was similar in the two groups. The largest nonrandomized experience with NHT shows a decrease in the incidence of positive surgical margins when used in high-risk patients with clinically localized carcinoma of the prostate. However, it does not have an impact on disease-free survival at a mean 24-month follow-up.",
author = "F. Civantos and S. Sadek and C. Obek and S. Lai and M. Soloway and S. Howell and M. Gleave and F. Labrie and W. Fair and A. D'Amico and N. Stone and David Grignon",
year = "1999",
language = "English (US)",
volume = "3",
pages = "201--206",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Neoadjuvant hormonal therapy prior to radical prostatectomy

AU - Civantos, F.

AU - Sadek, S.

AU - Obek, C.

AU - Lai, S.

AU - Soloway, M.

AU - Howell, S.

AU - Gleave, M.

AU - Labrie, F.

AU - Fair, W.

AU - D'Amico, A.

AU - Stone, N.

AU - Grignon, David

PY - 1999

Y1 - 1999

N2 - The US T(2b) study of 3 months of neoadjuvant hormonal therapy (NHT) showed a reduction in the likelihood of positive margins from 48% (control group) to 18% in the treated patients. Follow-up at 42 months shows that the cumulative relapse rate (prostate specific antigen) for 129 patients having NHT was not statistically different from that of the 126 control patients. Because the T(2b) study has been criticized for lacking central pathology review, we present a review of a series involving only one surgeon (MS) and one pathologist (FC) of NHT plus prostatectomy (109 patients) v prostatectomy alone (145 patients) with 24 months' follow-up. Positive margins were decreased from 38% in the untreated to 28% in the treated group, the only statistically significant difference in the results. Biochemical recurrence (PSA >0.2 ng/mL) was higher in the treated group, reflecting selection of more aggressive tumors for NHT, but the difference was not statistically significantly. The incidence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis was similar in the two groups. The largest nonrandomized experience with NHT shows a decrease in the incidence of positive surgical margins when used in high-risk patients with clinically localized carcinoma of the prostate. However, it does not have an impact on disease-free survival at a mean 24-month follow-up.

AB - The US T(2b) study of 3 months of neoadjuvant hormonal therapy (NHT) showed a reduction in the likelihood of positive margins from 48% (control group) to 18% in the treated patients. Follow-up at 42 months shows that the cumulative relapse rate (prostate specific antigen) for 129 patients having NHT was not statistically different from that of the 126 control patients. Because the T(2b) study has been criticized for lacking central pathology review, we present a review of a series involving only one surgeon (MS) and one pathologist (FC) of NHT plus prostatectomy (109 patients) v prostatectomy alone (145 patients) with 24 months' follow-up. Positive margins were decreased from 38% in the untreated to 28% in the treated group, the only statistically significant difference in the results. Biochemical recurrence (PSA >0.2 ng/mL) was higher in the treated group, reflecting selection of more aggressive tumors for NHT, but the difference was not statistically significantly. The incidence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis was similar in the two groups. The largest nonrandomized experience with NHT shows a decrease in the incidence of positive surgical margins when used in high-risk patients with clinically localized carcinoma of the prostate. However, it does not have an impact on disease-free survival at a mean 24-month follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0032755542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032755542&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032755542

VL - 3

SP - 201

EP - 206

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 3

ER -